AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29143869 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg with Ketanserin 40 mg
Number of subjects: 20
Study 26595710 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilization of rib fractures (SSRF)
Number of subjects: 70
Study 26595710 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 70
Study 24428733 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in CHRNA4
Number of subjects: 702
Study 24428733 — intervention group
Group type: COMPARATOR
Intervention: SNPs in other CHRNs (CHRNB2, CHRNA2, CHRNB3A6, CHRNA5A3B4)
Number of subjects: 702
Study 22498022 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-placed lay health advisor (LHA) intervention with home visits and newsletters
Number of subjects: 345
Study 22498022 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 345
Study 20639792 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula containing 0.8 g/100 mL short‐chain galacto‐oligosaccharides/long‐chain fructo‐oligosaccharides in a 9:1 ratio
Number of subjects: 160
Study 20639792 — intervention group
Group type: COMPARATOR
Intervention: Identical formula without prebiotic oligosaccharides
Number of subjects: 160
Study 17636280 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK230211 (1, 4, or 8 microg/24 h)
Number of subjects: 42
Study 17636280 — intervention group
Group type: COMPARATOR
Intervention: LNG (20 microg/24 h)
Number of subjects: 42
Study 15785272 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal quilting sutures
Number of subjects: 71
Study 15785272 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal closure
Number of subjects: 71
Study 11887119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed physician reminders (4 monthly reminders)
Number of subjects: 8325
Study 9388378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentian violet plus dibutyryl cAMP (GVcAMP)
Number of subjects: 19
Study 9388378 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine plus sugar (IS)
Number of subjects: 19
Study 7940487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration during CPB
Number of subjects: 11
Study 7940487 — intervention group
Group type: COMPARATOR
Intervention: No hemofiltration during CPB
Number of subjects: 11
Study 3359804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 110 mg retinyl palmitate (vitamin A supplementation)
Number of subjects: 0
Study 3359804 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group (control)
Number of subjects: 0
Study 29808613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle orientation programme (IG)
Number of subjects: 71
Study 29808613 — intervention group
Group type: COMPARATOR
Intervention: Routine guidelines of health services (CG)
Number of subjects: 71
Study 26652051 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone treatment
Number of subjects: 1124
Study 26652051 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended model
Number of subjects: 1124
Study 26652051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lab model
Number of subjects: 1124
Study 26652051 — intervention group
Group type: COMPARATOR
Intervention: IMPACT models
Number of subjects: 1124
Study 25377415 — intervention group
Group type: EXPERIMENTAL
Intervention: Telementored education through Google Glass (Group A)
Number of subjects: 18
Study 25377415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside education from the same expert (Group B)
Number of subjects: 18
Study 25377415 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 18
Study 23116343 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 43
Study 23116343 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 43
Study 23116343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajust
Number of subjects: 43
Study 23116343 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 43
Study 20160423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing with toothpaste (N=9)
Number of subjects: 17
Study 20160423 — intervention group
Group type: COMPARATOR
Intervention: Non-tooth brushing (Control group, N=8)
Number of subjects: 17
Study 18418239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive balloon postdilation (ABP)
Number of subjects: 88
Study 18418239 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive balloon postdilation (no ABP)
Number of subjects: 88
Study 16003035 — intervention group
Group type: COMPARATOR
Intervention: Mosaicplasty
Number of subjects: 47
Study 16003035 — intervention group
Group type: COMPARATOR
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 47
Study 14657616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 50
Study 14657616 — intervention group
Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 50
Study 11186472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 32
Study 11186472 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 32
Study 9100143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-year medical student preceptors
Number of subjects: 100
Study 9100143 — intervention group
Group type: COMPARATOR
Intervention: Faculty preceptors
Number of subjects: 100
Study 8161886 — intervention group
Group type: EXPERIMENTAL
Intervention: TP5
Number of subjects: 31
Study 8161886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3514363 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole (200 mg)
Number of subjects: 37
Study 3514363 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-iodine
Number of subjects: 37
Study 3514363 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 3401284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (BZF) 400-600 mg/day for 15-30 days
Number of subjects: 62
Study 3401284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (BZF) 400 mg/day for 15 days
Number of subjects: 62
Study 3401284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30838669 — intervention group
Group type: COMPARATOR
Intervention: Concurrent training based on physical activity recommendation from WHO (PAR group)
Number of subjects: 89
Study 30838669 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT group)
Number of subjects: 89
Study 30838669 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training with whole-body electromyostimulation (WB-EMS group)
Number of subjects: 89
Study 29165355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (HI-NI; 140 mL containing 12.9 mmol nitrate)
Number of subjects: 12
Study 25862491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) program, 12 group sessions, twice a week, 30 min each.
Number of subjects: 30
Study 25862491 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 24304733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine load (OML) test
Number of subjects: 353
Study 19734597 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 349
Study 19734597 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 349
Study 16983180 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment for 2 years
Number of subjects: 232
Study 15504380 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone followed by 400 microg oral misoprostol 2 days later
Number of subjects: 208
Study 11419426 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab plus stenting
Number of subjects: 300
Study 11419426 — intervention group
Group type: COMPARATOR
Intervention: placebo plus stenting
Number of subjects: 300
Study 9642335 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 128
Study 9642335 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 128
Study 9642335 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (placebo)
Number of subjects: 128
Study 8273924 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 20
Study 8273924 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal tube
Number of subjects: 20
Study 3814034 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 38
Study 3814034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29030001 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 203
Study 29030001 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal Endoscopic Microsurgery (TEM)
Number of subjects: 203
Study 29030001 — intervention group
Group type: COMPARATOR
Intervention: EMR of adenomas
Number of subjects: 203
Study 27288475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (VPR) 0.1 mg
Number of subjects: 163
Study 27288475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (VPR) 0.5 mg
Number of subjects: 163
Study 27288475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (VPR) 1 mg
Number of subjects: 163
Study 27288475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (VPR) 2 mg
Number of subjects: 163
Study 27288475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (VPR) 5 mg
Number of subjects: 163
Study 27288475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 24810871 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 48
Study 24810871 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 48
Study 23546172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 600 mg/m², D1 i.v. q21; Carboplatin, AUC 5, D1 i.v. q21 (Arm A)
Number of subjects: 135
Study 23546172 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,200 mg/m² D1, D8 i.v. q21; Vinorelbine 30 mg/m² D1, D8 i.v. q21 (Arm B)
Number of subjects: 135
Study 21219813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin at 2 IU/ml
Number of subjects: 76
Study 21219813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 76
Study 18596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfectionism program
Number of subjects: 127
Study 18596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy program
Number of subjects: 127
Study 18596551 — intervention group
Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 127
Study 16860852 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of carboplatin (7.5 AUC over 30 min) and paclitaxel (175 mg/m2 over 3 h) every 21 days
Number of subjects: 457
Study 16860852 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of carboplatin (7.5 AUC over 30 min) and paclitaxel (175 mg/m2 over 3 h) every 21 days
Number of subjects: 457
Study 16860852 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of carboplatin and paclitaxel
Number of subjects: 457
Study 16860852 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of carboplatin and paclitaxel
Number of subjects: 457
Study 12930333 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpura-free treatment with pulsed-dye laser
Number of subjects: 15
Study 12930333 — intervention group
Group type: COMPARATOR
Intervention: Purpura treatment with pulsed-dye laser
Number of subjects: 15
Study 12930333 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpura-free treatment with pulsed-dye laser (fewer than 250 pulses)
Number of subjects: 15
Study 12930333 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpura-free treatment with pulsed-dye laser (greater than 250 pulses)
Number of subjects: 15
Study 10325893 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training (125% of lactate threshold, 6 weeks)
Number of subjects: 16
Study 8704887 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated home visit and office intervention
Number of subjects: 93
Study 8704887 — intervention group
Group type: EXPERIMENTAL
Intervention: Office intervention
Number of subjects: 93
Study 8704887 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 1722785 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin (2,000,000 KIU loading dose, 500,000 KIU/h infusion until skin closure, plus 2,000,000 KIU in priming volume)
Number of subjects: 100
Study 1722785 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients with similar indication for surgery)
Number of subjects: 100
Study 1722785 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin in risk patients (redo-operations, infective endocarditis)
Number of subjects: 100
Study 1722785 — intervention group
Group type: COMPARATOR
Intervention: Control group for risk patients
Number of subjects: 100
Study 1722785 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 100
Study 1722785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 100
Study 1722785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dosage aprotinin (2,000,000 KIU during induction or in priming volume only)
Number of subjects: 100
Study 6918343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical prostaglandin E2 (1.5 mg in 50 ml 0.9% NaCl)
Number of subjects: 20
Study 6918343 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 20
Study 31845865 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril tert-butylamine tablets
Number of subjects: 20
Study 29338762 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly plus methotrexate for 36 weeks, followed by randomized treatment with etanercept 50 mg or 25 mg QW plus methotrexate or placebo plus methotrexate for 52 weeks.
Number of subjects: 0
Study 29338762 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg or 25 mg QW plus methotrexate
Number of subjects: 0
Study 29338762 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 0
Study 26706043 — intervention group
Group type: EXPERIMENTAL
Intervention: l-rhamnose (25.5 g/d)
Number of subjects: 13
Study 26706043 — intervention group
Group type: EXPERIMENTAL
Intervention: inulin (22.4 g/d)
Number of subjects: 13
Study 26706043 — intervention group
Group type: COMPARATOR
Intervention: control (no supplement)
Number of subjects: 13
Study 25319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal pattern similarity across intervening items during encoding
Number of subjects: 0
Study 25319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier trained to discriminate encoding patterns associated with faces versus objects
Number of subjects: 0
Study 25319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral priming experiment
Number of subjects: 0
Study 25319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual conditions (single context vs across context boundaries)
Number of subjects: 0
Study 22676207 — intervention group
Group type: EXPERIMENTAL
Intervention: High left atrial systolic force (LASF) defined as >95th percentile (50 Kdynes/cm(2))
Number of subjects: 1566
Study 22676207 — intervention group
Group type: COMPARATOR
Intervention: Normal left atrial systolic force (LASF)
Number of subjects: 1566
Study 22676207 — intervention group
Group type: EXPERIMENTAL
Intervention: High LASF
Number of subjects: 1566
Study 22676207 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score including absence or presence of aortic valve area and LV mass index
Number of subjects: 1566
Study 19608589 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic nCPAP
Number of subjects: 61
Study 19608589 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 61
Study 19608589 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic nCPAP (at 12 weeks)
Number of subjects: 61
Study 17509486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (up to 16 mg/24 h as a transdermal patch)
Number of subjects: 427
Study 17509486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (up to 4.5 mg/day orally)
Number of subjects: 427
Study 17509486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 16202898 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine (0.5 microg/kg loading dose over 20 minutes, followed by continuous infusion at 0.4 microg/kg/h)
Number of subjects: 28
Study 16202898 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine
Number of subjects: 28
Study 16202898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV saline at the same calculated loading and infusion rates)
Number of subjects: 28
Study 12031053 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing improvements including insulation, double-glazing, re-roofing, heating, ventilation, and electrical rewiring.
Number of subjects: 580
Study 12031053 — intervention group
Group type: EXPERIMENTAL
Intervention: Health surveys completed by community nurses, including SF-36 and GHQ 12 questionnaires.
Number of subjects: 580
Study 12031053 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires screening for health problems sent to all residents.
Number of subjects: 580
Study 9568047 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha treatment
Number of subjects: 29
Study 9568047 — intervention group
Group type: COMPARATOR
Intervention: Normal tissue
Number of subjects: 29
Study 8534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm lignocaine (37 degrees C)
Number of subjects: 60
Study 8534645 — intervention group
Group type: COMPARATOR
Intervention: Cold lignocaine (room temperature)
Number of subjects: 60
Study 2652231 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg methysergide
Number of subjects: 11
Study 2652231 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg verapamil
Number of subjects: 11
Study 2652231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1091123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (60 patients)
Number of subjects: 79
Study 1091123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (19 patients)
Number of subjects: 79
Study 30680627 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneological outpatient treatment (hydrotherapy and peloidotherapy)
Number of subjects: 139
Study 28317353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth‐alveolar bone grafts (Group A, n=24)
Number of subjects: 45
Study 28317353 — intervention group
Group type: COMPARATOR
Intervention: Conventional tooth transplantation (Group B, n=21)
Number of subjects: 45
Study 23116597 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐CBT
Number of subjects: 60
Study 23116597 — intervention group
Group type: COMPARATOR
Intervention: SHP
Number of subjects: 60
Study 22188532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX), 32 mg daily for 8 weeks
Number of subjects: 20
Study 22188532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22188532 — intervention group
Group type: COMPARATOR
Intervention: Ruboxistaurin (RBX) and Placebo
Number of subjects: 20
Study 21092474 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid 1800 mg daily for 12 weeks
Number of subjects: 236
Study 21092474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 19013300 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (1 mmol/kg lean body mass)
Number of subjects: 13
Study 19013300 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine plus glucose (25 g)
Number of subjects: 13
Study 19013300 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine alone
Number of subjects: 13
Study 19013300 — intervention group
Group type: COMPARATOR
Intervention: Glucose (25 g)
Number of subjects: 13
Study 19013300 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine plus glucose
Number of subjects: 13
Study 16315636 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily)
Number of subjects: 18
Study 16315636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12873924 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dose lidocaine spinal anesthesia
Number of subjects: 0
Study 12873924 — intervention group
Group type: COMPARATOR
Intervention: 3% 2‐chloroprocaine epidural anesthesia
Number of subjects: 0
Study 10363872 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated echocardiographic measurement of left ventricular function
Number of subjects: 0
Study 1899365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 micrograms/kg/hr for 24 hours)
Number of subjects: 104
Study 1899365 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (1 micrograms/kg/min for 24 hours)
Number of subjects: 104
Study 6309314 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (Ro 07‐0582, MISO)
Number of subjects: 436
Study 6309314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 6309314 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 436
Study 31942969 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training only
Number of subjects: 275
Study 31942969 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training combined with a virtual reality component
Number of subjects: 275
Study 31051504 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 + Trp (0.4 kcal/min)
Number of subjects: 16
Study 31051504 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 (0.3 kcal/min)
Number of subjects: 16
Study 31051504 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp (0.1 kcal/min)
Number of subjects: 16
Study 31051504 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 29364329 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment (supra and subgingival scaling and root‐planning and periodontal maintenance appointments)
Number of subjects: 210